UNCY (Unicycive Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 07, 2026)


UNCY Unicycive Therapeutics Inc UNCY
32 GF Score
Price $5.43
! 2 Warning Signs
View Full Analysis

What is Unicycive Therapeutics Tariff Resilience Score?

Unicycive Therapeutics UNCY +1.12% 32 Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus rates UNCY with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,368 Biotechnology companies, Unicycive Therapeutics ranks better than 90.35% on this metric.

Unicycive Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Unicycive Therapeutics has Unicycive Therapeutics, a biotech firm, has limited exposure to tariffs as its primary focus is on drug development. While it may face some supply chain risks, its operations are largely insulated from direct tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Unicycive Therapeutics might have Highly Resilient.

Unicycive Therapeutics  (NAS:UNCY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Unicycive Therapeutics Tariff Resilience Score Related Terms

UNCY vs MDWD, ARCT, NGEN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Unicycive Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's Tariff Resilience Score falls into.


UNCY
32GF Score
Unicycive Therapeutics Inc UNCY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Unicycive Therapeutics (UNCY) has a Tariff Resilience Score of 7 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Unicycive Therapeutics ranks #132 out of 1368 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Unicycive Therapeutics' Tariff Resilience Score too high?
Unicycive Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Unicycive Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Unicycive Therapeutics ranks #132 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Unicycive Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Unicycive Therapeutics' Tariff Resilience Score compare to MDWD and ARCT?
According to the Biotechnology industry distribution chart, Unicycive Therapeutics ranks #132 out of 1368 companies for Tariff Resilience Score. This places Unicycive Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Unicycive Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unicycive Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unicycive Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unicycive Therapeutics stock overvalued right now?
Unicycive Therapeutics (UNCY) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Unicycive Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Unicycive Therapeutics (UNCY), the current Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unicycive Therapeutics Business Description

Address 1975 W. El Camino Real, Suite 204, Mountain View, CA, USA, 94040
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
32GF Score

Get the complete analysis for UNCY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.43
Price